Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib Phase 2 in Moderate-to-Severe Plaque Psoriasis
NCT04612699Phase 2Completed
- Sponsor
- Zelgen
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of jaktinib in plaque psoriasis (4 arms), sponsored by Zelgen. Primary endpoint: Proportion of participants achieving >= 75% improvement in Psoriasis Area and Severity Index at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04612699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612699.